NCT00168922

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Phase II Study to Determine the Efficacy of Bendamustin (Ribomustin) in Patients With Recurrent Small Cell Bronchial Carcinoma After Cytostatic Polychemotherapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (planned)
• Sponsor: Charite University, Berlin, Germany · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Determination of response rate Assessment of toxicity and determination of "time to progression"

Detailed description

Phase II Study to determine the efficacy of Bendamustin(Ribomustin) in patients with recurrent small cell bronchial carcinoma after cytostatic polychemotherapy

Conditions

• Recurrent Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Bendamustin/Ribomustin

Timeline

• Start date: 2001-02-01
• Completion: 2006-12-01
• First posted: 2005-09-15
• Last updated: 2006-04-27

Locations

1 site across 1 country: Germany